APA (7th ed.) Citation

Liu, D., Zhou, J., Wang, Y., Li, M., Jiang, H., Liu, Y., . . . Wang, L. (2022). Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: A dose-escalation, dose-expansion, and clinical-expansion phase 1 trial. BMC Medicine, 20(1), 1. https://doi.org/10.1186/s12916-022-02605-9

Chicago Style (17th ed.) Citation

Liu, Dan, et al. "Bifunctional Anti-PD-L1/TGF-βRII Agent SHR-1701 in Advanced Solid Tumors: A Dose-escalation, Dose-expansion, and Clinical-expansion Phase 1 Trial." BMC Medicine 20, no. 1 (2022): 1. https://doi.org/10.1186/s12916-022-02605-9.

MLA (9th ed.) Citation

Liu, Dan, et al. "Bifunctional Anti-PD-L1/TGF-βRII Agent SHR-1701 in Advanced Solid Tumors: A Dose-escalation, Dose-expansion, and Clinical-expansion Phase 1 Trial." BMC Medicine, vol. 20, no. 1, 2022, p. 1, https://doi.org/10.1186/s12916-022-02605-9.